Week of May 4-10, 2026: 10 IBD research stories worth your attention
This week brought a mix of practical insights and early-stage research that caught my attention. Having lived with Crohn’s since 2002, I found myself particularly drawn to the real-world data on drug access barriers — something every IBD patient navigates — and the surprising findings about NSAIDs that challenge conventional wisdom. The preclinical and Phase 2 work was interesting to track but, as usual, years away from changing how I manage my disease.
Here’s what stood out from my reading this week, with the clinical stage and practical implications clearly marked for each.
Drug Access Barriers Are Shaping IBD Care More Than Clinical Evidence
This was real-world data examining how insurance restrictions and prior authorization requirements influence IBD treatment decisions across multiple health systems. The analysis found that access barriers often override clinical considerations when selecting biologics, with patients frequently receiving treatments based on formulary coverage rather than disease phenotype or mechanism of action.
What this means for me right now: This validates what I’ve experienced firsthand during my transition from Remicade to Rinvoq in 2026 — insurance approval timelines and step therapy requirements shaped the process as much as clinical factors did. It’s useful data for understanding why treatment decisions sometimes feel disconnected from the research we read about optimal sequencing.
The main limitation: The study doesn’t quantify how access barriers affect clinical outcomes long-term, only that they influence prescribing patterns.
Appendectomy vs. Upadacitinib for Biologic-Refractory Ulcerative Colitis
This was Phase 2 data comparing prophylactic appendectomy to upadacitinib (Rinvoq) in UC patients who hadn’t responded to biologics. The study followed 156 patients for 12 months, finding similar rates of clinical remission (42% appendectomy vs. 38% upadacitinib) but different safety profiles.
What this means for me right now: Nothing changes. This is early-stage data comparing two interventions in a specific UC population, and I have Crohn’s disease. Even for UC patients, this would need Phase 3 confirmation before influencing treatment decisions.
The main limitation: Single-center study with a relatively small sample size, and the mechanism behind appendectomy’s potential benefit in UC remains unclear.
NSAIDs May Be Less Dangerous in IBD Than Previously Thought
This was an observational study using insurance claims data from over 40,000 IBD patients, examining NSAID use and flare rates over a two-year period. The analysis found no statistically significant increase in hospitalizations or steroid use among IBD patients taking NSAIDs compared to those avoiding them.
What this means for me right now: This challenges the blanket “never take NSAIDs” advice I’ve received for over 20 years, but it doesn’t change my current approach. I’d want to see this replicated in a prospective study before considering NSAIDs for pain management.
The main limitation: Claims data can’t capture disease activity scores or endoscopic findings, so the study may miss subclinical inflammation that doesn’t result in hospitalization.
First-Line Therapy Options for Moderate-Severe UC
This was a meta-analysis comparing different first-line biologics and JAK inhibitors in treatment-naive patients with moderate to severe ulcerative colitis. The analysis included 12 randomized controlled trials with over 3,000 patients, finding similar efficacy across TNF inhibitors, integrin blockers, and JAK inhibitors at 8-12 weeks.
What this means for me right now: This doesn’t affect my current Crohn’s management, but it’s useful context for understanding how treatment algorithms are evolving in UC. The lack of clear superiority among first-line options suggests other factors — like access, side effect profiles, or patient preference — become more important.
The main limitation: Short follow-up periods in most included studies, and the analysis couldn’t account for differences in long-term safety or durability.
Higher Blood Clot Risk After Colon Cancer Surgery in IBD
This was real-world data from a large health system analyzing venous thromboembolism rates in IBD patients undergoing colorectal cancer surgery. The study found a 3.2-fold higher risk of blood clots compared to non-IBD patients having similar surgery, with elevated risk persisting for more than 12 months post-operatively.
What this means for me right now: This is relevant context for long-term IBD management, particularly given the increased colorectal cancer risk in IBD. It doesn’t change my current surveillance schedule, but it’s information worth having if I ever face surgical decisions.
The main limitation: Single health system data, and the study couldn’t fully control for differences in disease activity or medication use between IBD and non-IBD patients.
J&J Advances Dual-Antibody Therapy to Phase 3 Despite Mixed Phase 2 Results
Johnson & Johnson announced plans to move their combination therapy (Tremfya + Simponi) into Phase 3 trials for both Crohn’s disease and ulcerative colitis, despite the Phase 2 DUET studies missing their primary endpoints. The company cited secondary endpoint data and biomarker findings as justification for the advancement.
What this means for me right now: Nothing changes. Even if Phase 3 trials begin this year, we’re looking at 3-4 years minimum before potential approval. The fact that they’re advancing despite Phase 2 misses makes me more cautious about eventual efficacy data.
The main limitation: No new efficacy data was presented — this is a business decision based on existing Phase 2 results that didn’t meet primary endpoints.
Deep Learning Models for Endoscopic IBD Assessment Show Promise
This was a meta-analysis of 12 studies evaluating artificial intelligence models for scoring endoscopic disease activity in IBD. The models achieved high accuracy rates (AUROC up to 0.971 for Crohn’s stricture detection) and demonstrated potential for reducing inter-observer variability in endoscopic scoring.
What this means for me right now: This is interesting but doesn’t change my experience with colonoscopies or how my gastroenterologist interprets the findings. These are research tools that may eventually improve consistency in clinical trials or specialist training.
The main limitation: Most studies were single-center with small datasets, and none evaluated how AI scoring affects clinical decision-making or patient outcomes.
Seres Therapeutics Presents Preclinical Data on SER-603 Live Biotherapeutic
This was preclinical data presented at Digestive Disease Week on SER-603, a cultivated live biotherapeutic designed to target microbial functions linked to mucosal healing in IBD. The company reported positive results in animal models but provided limited details on the specific mechanisms or efficacy measures.
What this means for me right now: Nothing changes. This is animal data for a microbiome-based therapy that’s years away from human testing. Microbiome approaches have shown promise in preclinical work before without translating to clinical benefit.
The main limitation: Animal models don’t predict human efficacy for microbiome interventions, and no timeline for human studies was provided.
Cornell Researchers Discover Immune Tolerance Switch
This was preclinical research from Weill Cornell Medicine identifying a molecular pathway that controls immune tolerance in the gut. The researchers found that manipulating this “switch” could reduce inflammation in mouse models of IBD and food allergy.
What this means for me right now: Nothing changes. This is basic science research that helps explain how immune tolerance works but is years away from therapeutic applications. Understanding mechanisms is valuable for long-term drug development but doesn’t affect current treatment options.
The main limitation: Mouse models of IBD don’t reliably predict human therapeutic benefit, and no human studies are planned yet.
This week reinforced something I’ve learned over 24 years with Crohn’s: the most immediately relevant research often isn’t the most scientifically novel. The drug access barriers analysis and NSAID safety data affect how I think about my care today, while the preclinical discoveries are interesting to track but won’t influence my decisions for years. That’s not a criticism — it’s just the reality of how medical research translates to patient care.
